Guangzhou Wondfo BiotechLtd Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Guangzhou Wondfo BiotechLtd de 27.5% y 21.1% por año respectivamente. Se prevé que el BPA crezca en un 26.9% al año. Se espera que la rentabilidad financiera sea de 13.9% en 3 años.

Información clave

27.5%

Tasa de crecimiento de los beneficios

26.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	26.7%
Tasa de crecimiento de los ingresos	21.1%
Rentabilidad financiera futura	13.9%
Cobertura de analistas	Low
Última actualización	29 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture

Nov 18

Guangzhou Wondfo BiotechLtd's (SZSE:300482) Shareholders May Want To Dig Deeper Than Statutory Profit

Nov 01

Cautious Investors Not Rewarding Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Performance Completely

Sep 06

Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture

Jul 27

Guangzhou Wondfo BiotechLtd's (SZSE:300482) Solid Earnings May Rest On Weak Foundations

Apr 29

A Piece Of The Puzzle Missing From Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price

Mar 27

There Are Reasons To Feel Uneasy About Guangzhou Wondfo BiotechLtd's (SZSE:300482) Returns On Capital

Feb 29

Previsiones de crecimiento de beneficios e ingresos

SZSE:300482 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	4,775	1,013	N/A	1,086	4
12/31/2025	3,951	818	N/A	917	4
12/31/2024	3,265	649	N/A	927	4
9/30/2024	2,942	524	107	538	N/A
6/30/2024	2,852	509	230	624	N/A
3/31/2024	2,794	502	289	664	N/A
12/31/2023	2,765	488	-104	329	N/A
9/30/2023	2,989	357	116	569	N/A
6/30/2023	3,136	354	-56	459	N/A
3/31/2023	3,887	497	1,268	1,818	N/A
1/1/2023	5,681	1,197	1,099	1,682	N/A
9/30/2022	5,550	1,247	905	1,472	N/A
6/30/2022	5,538	1,257	898	1,461	N/A
3/31/2022	5,290	1,383	-270	287	N/A
12/31/2021	3,361	634	208	665	N/A
9/30/2021	3,145	695	18	621	N/A
6/30/2021	3,060	741	-1	557	N/A
3/31/2021	2,956	692	113	594	N/A
12/31/2020	2,811	634	642	1,062	N/A
9/30/2020	2,821	663	657	886	N/A
6/30/2020	2,711	630	885	1,053	N/A
3/31/2020	2,172	413	595	775	N/A
12/31/2019	2,072	387	131	310	N/A
9/30/2019	1,921	375	175	329	N/A
6/30/2019	1,817	352	137	296	N/A
3/31/2019	1,748	325	97	232	N/A
12/31/2018	1,650	308	117	248	N/A
9/30/2018	1,542	280	69	198	N/A
6/30/2018	1,498	264	N/A	175	N/A
3/31/2018	1,323	231	N/A	186	N/A
12/31/2017	1,145	211	N/A	169	N/A
9/30/2017	921	181	N/A	51	N/A
6/30/2017	747	174	N/A	100	N/A
3/31/2017	624	154	N/A	116	N/A
12/31/2016	547	145	N/A	112	N/A
9/30/2016	525	158	N/A	143	N/A
6/30/2016	486	147	N/A	141	N/A
3/31/2016	450	131	N/A	145	N/A
12/31/2015	429	125	N/A	132	N/A
9/30/2015	382	106	N/A	108	N/A
6/30/2015	380	105	N/A	99	N/A
3/31/2015	365	96	N/A	107	N/A
12/31/2014	365	98	N/A	104	N/A
12/31/2013	248	59	N/A	101	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (27.5% al año) de 300482 es superior a la tasa de ahorro (2.8%).

Beneficios vs. Mercado: Se prevé que los beneficios (27.5% al año) de 300482 crezcan más rápidamente que el mercado CN (26.2% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de 300482 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (21.1% al año) de 300482 crezcan más rápidamente que los del mercado CN (13.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (21.1% al año) de 300482 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 300482 sea baja dentro de 3 años (13.9%).

Guangzhou Wondfo BiotechLtd Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 7.6% to CN¥33.55

Price target decreased to CN¥60.42

Consensus revenue estimates increase by 34%

Price target decreased to CN¥68.96

Recent updates

Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture

High number of new directors

Guangzhou Wondfo BiotechLtd's (SZSE:300482) Shareholders May Want To Dig Deeper Than Statutory Profit

Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in 3Q 2023)

New minor risk - Share price stability

Guangzhou Wondfo Biotech Co.,Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 18%

Cautious Investors Not Rewarding Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Performance Completely

Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.30 in 2Q 2023)

Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture

Price target decreased by 7.6% to CN¥33.55

Guangzhou Wondfo Biotech Co.,Ltd to Report First Half, 2024 Results on Aug 14, 2024

Guangzhou Wondfo BiotechLtd's (SZSE:300482) Solid Earnings May Rest On Weak Foundations

Investor sentiment improves as stock rises 20%

First quarter 2024 earnings released: EPS: CN¥0.49 (vs CN¥0.46 in 1Q 2023)

New minor risk - Shareholder dilution

Guangzhou Wondfo Biotech Co.,Ltd to Report Q1, 2024 Results on Apr 22, 2024

A Piece Of The Puzzle Missing From Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price

There Are Reasons To Feel Uneasy About Guangzhou Wondfo BiotechLtd's (SZSE:300482) Returns On Capital

Investor sentiment deteriorates as stock falls 15%

Guangzhou Wondfo Biotech Co.,Ltd to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Guangzhou Wondfo Biotech Co.,Ltd to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.62 in 2Q 2022)

Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 50 million worth of its shares.

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 20% undervalued after recent price drop

Now 20% undervalued

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Now 23% undervalued

Price target decreased to CN¥60.42

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.16 in 3Q 2021)

Investor sentiment improved over the past week

Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 50 million worth of its shares.

Second quarter 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.90 in 2Q 2021)

Guangzhou Wondfo Biotech Co.,Ltd announced that it expects to receive CNY 1 billion in funding

Guangzhou Wondfo Biotech Co.,Ltd Announces Cash Dividend, Payable on 14 June 2022

Guangzhou Wondfo Biotech Co.,Ltd Approves Cash Dividend for the Year 2021

Consensus revenue estimates increase by 34%

Less than half of directors are independent

Guangzhou Wondfo Biotech Co.,Ltd. Announces Profit Distribution Proposal for 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.27 in 3Q 2020)

Price target decreased to CN¥68.96

Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 80 million worth of its shares.

Second quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.79 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Guangzhou Wondfo Biotech Co.,Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 26 May 2021

First quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.29 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥1.87 (vs CN¥1.14 in FY 2019)

Guangzhou Wondfo Biotech Co.,Ltd to Report Fiscal Year 2020 Results on Mar 31, 2021

Wondfo Rams Up Neutralizing Antibody, Antigen and PCR Tests to Address the Evolving Demands for COVID-19 Testing Globally

New 90-day high: CN¥95.02

New 90-day high: CN¥90.79

Investor sentiment improved over the past week

New 90-day low: CN¥74.05

Third quarter earnings released

New 90-day low: CN¥81.99

New 90-day low: CN¥83.05

New 90-day low - CN¥84.82

First half earnings released

Guangzhou Wondfo Biotech Co.,Ltd to Report First Half, 2020 Results on Aug 28, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas